SCHEMBL3773704

SCHEMBL3773704

O=C(CN1CCN(c2ccc(F)cc2F)CC1)N1CCN(C2CCCCC2)CC1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GRM5 P41594 2/20 0.48
DPP4 P27487 1/20 0.47
DPP9 Q86TI2 1/20 0.47
HTT P42858 1/20 0.46
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
TP53 P04637 1/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
ACKR3 P25106 3/20 0.45
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
CALCA P06881 1/20 0.43
PARP1 P09874 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3770906 0.87 ALDH1A1 (0.57) HTTMEN1KMT2ATP53ALOX15
SCHEMBL13004958 0.85 KMT2A (0.56) MEN1KMT2ATP53ALOX15TSHR
SCHEMBL3775693 0.84 ALDH1A1 (0.57) HTTMEN1KMT2AALDH1A1PARP1
SCHEMBL3776110 0.84 MEN1 (0.61) MEN1KMT2AALDH1A1KDM4E
SCHEMBL3768876 0.83 KMT2A (0.56) MEN1KMT2ATP53ALOX15TSHR
SCHEMBL13004959 0.83 MEN1 (0.62) MEN1KMT2AALDH1A1KDM4E
SCHEMBL3777242 0.83 MEN1 (0.55) HTTMEN1KMT2ATSHRALDH1A1
SCHEMBL3769377 0.83 SLC6A9 (0.54) HTTMEN1KMT2AALDH1A1CALCA
SCHEMBL3767704 0.81 ALDH1A1 (0.47) HTTACKR3ALDH1A1KDM4EPARP1
SCHEMBL13004965 0.81 MEN1 (0.56) HTTMEN1KMT2ATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 GRM5 647/4885DPP4 431/4885DPP9 1214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.